Tu Xu

4.2k citations
29 papers · 2.4k · 3 hit papers · h-index 12

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 2%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Tu Xu

26 papers receiving 2.4k citations

Hit Papers

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study 2019 · 456 citations
4560+2+5Years since publication2505007501000

Peers

Tu Xu
Comparison fields: 5 of 100
  • Hematology 1.9k
  • Genetics 496
  • Molecular Biology 1.3k
  • Public Health, Environmental and Occupational Health 481
  • Oncology 438
Replace Hareth Nahi with:
Hareth Nahi Sweden
Todd M. Cooper United States
Theo M. de Witte Netherlands
Naval Daver United States
Vamsi Kota United States
Sanne Lugthart Netherlands
Jeffrey L. Wolf United States
M. Naveed Shaik United States
Guillermo Montalban‐Bravo United States
Christoph Heuck United States
Tu Xu relative to Hareth Nahi Sweden Hareth Nahi's profile →
Citations per field
00.5×3.7×
Hareth Nahi · 1×
Citations per year

Countries citing papers authored by Tu Xu

Since Specialization
Citations

This map shows the geographic impact of Tu Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tu Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tu Xu more than expected).

Fields of papers citing papers by Tu Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tu Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tu Xu. The network helps show where Tu Xu may publish in the future.

Co-authors

The 25 scholars most cited alongside Tu Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tu Xu Line = papers co-authored together Tu Xu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Hit paper breakdown →
20181175
2
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Hit paper breakdown →
2018498
3
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Hit paper breakdown →
2019456
4 201749
5 201534
6 201832
7 201630
8 201425
9 201825
10 201423
11 201417
12 202313
13 20188
14 20245
15 20174
16 20134
17 20174
18 20183
19 20232
20 20192

About Tu Xu

Tu Xu is a scholar working on Molecular Biology, Hematology, Oncology, Statistics and Probability and Pulmonary and Respiratory Medicine, having authored 29 papers that have together received 2.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Statistical Methods in Clinical Trials (6 papers), Neutropenia and Cancer Infections (6 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Statistical Methods and Inference (3 papers) and Histone Deacetylase Inhibitors Research (3 papers). The work is most often cited by research in Hematology (1.9k citations), Genetics (496 citations), Molecular Biology (1.3k citations), Public Health, Environmental and Occupational Health (481 citations) and Oncology (438 citations). Tu Xu has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Andrew H. Wei, Brenda Chyla, Jalaja Potluri, Marina Konopleva, Anthony Letai, Daniel A. Pollyea, Brian A. Jonas, Keith W. Pratz, Courtney D. DiNardo and Hagop M. Kantarjian. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of the American Thoracic Society, Journal of Thoracic Oncology and Pharmaceutical Statistics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact